See more : Pershing Square Holdings, Ltd. (PSH.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Altamira Therapeutics Ltd. (CYTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altamira Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Bank IBK Indonesia Tbk (AGRS.JK) Income Statement Analysis – Financial Results
- Full Alliance Group, Inc. (FAGI) Income Statement Analysis – Financial Results
- Canadian Nexus Team Ventures Corp. (LGMFF) Income Statement Analysis – Financial Results
- ImmuPharma plc (IMM.L) Income Statement Analysis – Financial Results
- Vifor Pharma AG (GNHAY) Income Statement Analysis – Financial Results
Altamira Therapeutics Ltd. (CYTO)
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 305.62K | 63.88K | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.44M | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.14M | -2.18M | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -372.44% | -3,407.33% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.04M | 19.68M | 8.94M | 2.86M | 3.33M | 6.69M | 19.21M | 24.78M | 26.54M | 17.70M | 13.25M | 3.99M |
| General & Administrative | 3.09M | 3.52M | 4.90M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Selling & Marketing | 15.35K | 2.38M | 1.50M | 95.66K | 113.96K | 43.82K | 199.48K | 45.65K | 72.56K | 237.72K | 479.03K | 86.23K |
| SG&A | 3.12M | 5.90M | 6.39M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Other Expenses | 0.00 | -586.73K | -409.93K | 0.00 | 0.00 | 215.72K | 87.59K | 34.06K | 62.20K | 73.43K | 49.42K | 34.28K |
| Operating Expenses | 6.54M | 24.99M | 14.92M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Cost & Expenses | 6.54M | 26.44M | 17.16M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Interest Income | 730.20K | 969.00 | 3.22K | 258.00 | 17.88K | 0.00 | 53.57K | 67.57K | 37.00K | 52.13K | 74.04K | 5.83K |
| Interest Expense | 0.00 | 911.87K | 189.70K | 135.15K | 28.63K | 1.07M | 1.64M | 828.55K | 8.00K | 49.64K | 50.18K | 0.00 |
| Depreciation & Amortization | 5.92M | 118.89K | 76.36K | 20.04K | 30.82K | 72.71K | 122.78K | 97.60K | 92.78K | 73.98K | 37.52K | 9.24K |
| EBITDA | -1.35M | -17.64M | -6.72M | -5.26M | -7.24M | -10.95M | -24.31M | -30.06M | -30.84M | -22.19M | -14.51M | -4.60M |
| EBITDA Ratio | 0.00% | -8,511.54% | -26,643.21% | -3,027.89% | 12,930.83% | -865.25% | -7,548.97% | 7,260.41% | 46,031.34% | -737.55% | 0.00% | 0.00% |
| Operating Income | -5.92M | -26.13M | -17.10M | -5.28M | -7.26M | -10.95M | -24.36M | -30.22M | -30.88M | -22.19M | -14.62M | -4.61M |
| Operating Income Ratio | 0.00% | -8,550.76% | -26,767.78% | -3,028.04% | 12,962.76% | -865.25% | -7,565.61% | 7,300.31% | 46,086.57% | -737.59% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.35M | -645.64K | -1.46M | -2.94M | 433.41K | -380.10K | -66.00K | -570.03K | 1.17M | 4.01M | -82.89K | 8.09K |
| Income Before Tax | -7.27M | -26.54M | -17.37M | -8.22M | -6.83M | -11.33M | -24.43M | -30.79M | -29.71M | -18.19M | -14.70M | -4.60M |
| Income Before Tax Ratio | 0.00% | -8,683.69% | -27,188.48% | -4,712.11% | 12,188.82% | -895.28% | -7,586.10% | 7,438.00% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -10.33K | 21.62K | -21.28K | -193.84K | 162.18K | -17.77K | -131.06K | -84.78K | -892.18K | 305.75K | 0.00 |
| Net Income | -7.27M | -26.53M | -17.39M | -8.20M | -6.63M | -11.50M | -24.41M | -30.66M | -29.71M | -18.19M | -15.00M | -4.60M |
| Net Income Ratio | 0.00% | -8,680.31% | -27,222.33% | -4,699.91% | 11,842.68% | -908.09% | -7,580.58% | 7,406.34% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| EPS | -14.81 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| EPS Diluted | -14.80 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| Weighted Avg Shares Out | 491.00K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
| Weighted Avg Shares Out (Dil) | 491.26K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
Why Is Altamira Therapeutics (CYTO) Stock Up 45% Today?
Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Thursday despite a lack of news from the RNA-based therapeutics company. There are no new press releases from Altamira Therapeutics that explain why the company's shares are rising today.
Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors
CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors. The announcement follows a series of...
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11
HAMILTON, BERMUDA / ACCESSWIRE / May 1, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, chairman, and CEO Thomas Meyer will be...
Ankyra Therapeutics Presents Preliminary Canine Clinical Data with cANK-101 Supporting Therapeutic Potential of Anchored Immunotherapy
BOSTON--(BUSINESS WIRE)--Ankyra Therapeutics, a pre-clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for cytokine drugs, announced today that it will be presenting data from a canine clinical trial of cANK-101 at the American Association for Cancer Research...
3 Methods for Finding Penny Stocks to Buy and Hold
Use these strategies for making money with penny stocks in 2023 The post 3 Methods for Finding Penny Stocks to Buy and Hold appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Altamira Therapeutics (CYTO) Stock Up 64% Today?
Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Wednesday after providing an update on its SemaPhore nanoparticle technology. According to a press release from Altamira Therapeutics, SemaPhore has the potential to serve the mRNA applications market.
4 Penny Stocks To Watch If You're Playing The “Stock Market Game”
Penny stocks, the stock market game & what traders are watching this week. The post 4 Penny Stocks To Watch If You're Playing The “Stock Market Game” appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
How to Set Expectations For Penny Stocks Trading
Use these tips for setting penny stocks investing expectations The post How to Set Expectations For Penny Stocks Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing
House dust mite study shows statistically significant reduction in symptoms vs. no protection Grass pollen study shows faster onset of action and superior efficacy ratings by patients Bentrio® shows wider nasal cavity distribution, for 3.5 x more time, vs saline...
Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
New, trends and future of RNA-based therapeutics Company's OligoPhoreTM / SemaPhoreTM polyplexes provide for efficient delivery of siRNA payloads into extrahepatic target cells Company's latest research and insights into RNA-based therapies Alternatives to LNPs and how Altamira's proprietary R&D is...
Source: https://incomestatements.info
Category: Stock Reports